{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T08:46:16Z","timestamp":1782290776900,"version":"3.54.5"},"posted":{"date-parts":[[2026,6,24]]},"group-title":"In Review","reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,3]]},"abstract":"<title>Abstract<\/title>\n                <p>The ongoing evolution of SARS-CoV-2, particularly the emergence of Omicron subvariants, compromised the effectiveness of many therapeutic antibodies. In this study, we employed a structure-guided computational design strategy to systematically optimize the COV2-2196 antibody for improved neutralization of Omicron variants. Through iterative rounds of computational design and experimental validation, we identified key paratope mutations that restored and enhanced antibody binding and neutralization potency against resistant viral strains. Cryo-EM structural analysis revealed the molecular basis for these improvements, highlighting how targeted modifications can accommodate epitope changes introduced by viral evolution. Our approach demonstrates that effective antibody optimization can be achieved using accessible computational resources, providing a practical framework for rapid therapeutic development. These findings underscore the potential of structure-based design to address challenges posed by viral antigenic drift and support the development of broadly effective antibody therapeutics for emerging infectious diseases.<\/p>","DOI":"10.21203\/rs.3.rs-9917568\/v1","type":"posted-content","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:47:57Z","timestamp":1782287277000},"source":"Crossref","is-referenced-by-count":0,"title":["Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron Variants"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3270-1587","authenticated-orcid":false,"given":"Jesper","family":"Pallesen","sequence":"first","affiliation":[{"name":"The Wistar Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2626-6590","authenticated-orcid":false,"given":"Jianqiu","family":"Du","sequence":"additional","affiliation":[{"name":"The Wistar Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4706-439X","authenticated-orcid":false,"given":"Yuanhan","family":"Wu","sequence":"additional","affiliation":[{"name":"The Wistar Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Ghosh","sequence":"additional","affiliation":[{"name":"The Wistar Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Bayruns","sequence":"additional","affiliation":[{"name":"The Wistar Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopak","family":"Sadeesh","sequence":"additional","affiliation":[{"name":"The Wistar Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-8512","authenticated-orcid":false,"given":"David","family":"Weiner","sequence":"additional","affiliation":[{"name":"The Wistar Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"106560","DOI":"10.1016\/j.intimp.2020.106560","article-title":"Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids","volume":"84","author":"Saghazadeh A","year":"2020","unstructured":"Saghazadeh A, Rezaei N (2020) Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids. Int Immunopharmacol 84:106560","journal-title":"Int Immunopharmacol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto D","year":"2020","unstructured":"Pinto D et al (2020) Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583:290\u2013295","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab","volume":"385","author":"Gupta A","year":"2021","unstructured":"Gupta A et al (2021) Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med 385:1941\u20131950","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost SJ","year":"2020","unstructured":"Zost SJ et al (2020) Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584:443\u2013449","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum A","year":"2020","unstructured":"Baum A et al (2020) REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370:1110\u20131115","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"100255","DOI":"10.1016\/j.xcrm.2021.100255","article-title":"Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016","volume":"2","author":"Starr TN","year":"2021","unstructured":"Starr TN, Greaney AJ, Dingens AS, Bloom JD (2021) Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med 2:100255","journal-title":"Cell Rep Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41467-020-20602-5","article-title":"A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein","volume":"12","author":"Kim C","year":"2021","unstructured":"Kim C et al (2021) A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun 12:288","journal-title":"Nat Commun"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19","volume":"386","author":"Levin MJ","year":"2022","unstructured":"Levin MJ et al (2022) Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med 386:2188\u20132200","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa","volume":"603","author":"Viana R","year":"2022","unstructured":"Viana R et al (2022) Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603:679\u2013686","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni E","year":"2022","unstructured":"Cameroni E et al (2022) Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602:664\u2013670","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection","volume":"608","author":"Cao Y","year":"2022","unstructured":"Cao Y et al (2022) BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608:593\u2013602","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani S","year":"2022","unstructured":"Iketani S et al (2022) Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604:553\u2013556","journal-title":"Nature"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan LA","year":"2022","unstructured":"VanBlargan LA et al (2022) An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med 28:490\u2013495","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/s41591-022-01911-2","article-title":"Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa","volume":"28","author":"Tegally H","year":"2022","unstructured":"Tegally H et al (2022) Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med 28:1785\u20131790","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Wang Q","year":"2022","unstructured":"Wang Q et al (2022) Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 608:603\u2013608","journal-title":"Nature"},{"key":"ref16","author":"Tuekprakhon A","year":"2022","unstructured":"Tuekprakhon A et al (2022) Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433 e13"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1038\/s41467-023-39890-8","article-title":"Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants","volume":"14","author":"Moriyama S","year":"2023","unstructured":"Moriyama S et al (2023) Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants. Nat Commun 14:4198","journal-title":"Nat Commun"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41586-024-07385-1","article-title":"Computationally restoring the potency of a clinical antibody against Omicron","volume":"629","author":"Desautels TA","year":"2024","unstructured":"Desautels TA et al (2024) Computationally restoring the potency of a clinical antibody against Omicron. Nature 629:878\u2013885","journal-title":"Nature"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1038\/s41467-022-33309-6","article-title":"DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2","volume":"13","author":"Parzych EM","year":"2022","unstructured":"Parzych EM et al (2022) DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2. Nat Commun 13:5886","journal-title":"Nat Commun"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2294860","DOI":"10.1080\/22221751.2023.2294860","article-title":"In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates","volume":"13","author":"Patel A","year":"2024","unstructured":"Patel A et al (2024) In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates. Emerg Microbes Infect 13:2294860","journal-title":"Emerg Microbes Infect"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1038\/s41591-025-03969-0","article-title":"Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial","volume":"31","author":"Tebas P","year":"2025","unstructured":"Tebas P et al (2025) Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial. Nat Med 31:4150\u20134159","journal-title":"Nat Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e1006112","DOI":"10.1371\/journal.pcbi.1006112","article-title":"RosettaAntibodyDesign (RAbD): A general framework for computational antibody design","volume":"14","author":"Adolf-Bryfogle J","year":"2018","unstructured":"Adolf-Bryfogle J et al (2018) RosettaAntibodyDesign (RAbD): A general framework for computational antibody design. PLoS Comput Biol 14:e1006112","journal-title":"PLoS Comput Biol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh CL","year":"2020","unstructured":"Hsieh CL et al (2020) Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369:1501\u20131505","journal-title":"Science"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1038\/s41467-023-39267-x","article-title":"Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection","volume":"14","author":"Guo Y","year":"2023","unstructured":"Guo Y et al (2023) Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection. Nat Commun 14:3537","journal-title":"Nat Commun"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.celrep.2014.04.001","article-title":"Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike","volume":"7","author":"Scharf L","year":"2014","unstructured":"Scharf L et al (2014) Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep 7:785\u2013795","journal-title":"Cell Rep"},{"key":"ref26","author":"Scheres SH","year":"2012","unstructured":"Scheres SH (2012) RELION: implementation of a Bayesian approach to cryo-EM structure determination. J Struct Biol 180, 519\u2009\u2013\u200930"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jsb.2015.08.008","article-title":"CTFFIND4: Fast and accurate defocus estimation from electron micrographs","volume":"192","author":"Rohou A","year":"2015","unstructured":"Rohou A, Grigorieff N (2015) CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol 192:216\u2013221","journal-title":"J Struct Biol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nmeth.4169","article-title":"cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination","volume":"14","author":"Punjani A","year":"2017","unstructured":"Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA (2017) cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods 14:290\u2013296","journal-title":"Nat Methods"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e4792","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX: Tools for structure building and analysis","volume":"32","author":"Meng EC","year":"2023","unstructured":"Meng EC et al (2023) UCSF ChimeraX: Tools for structure building and analysis. Protein Sci 32:e4792","journal-title":"Protein Sci"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley P","year":"2004","unstructured":"Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126\u20132132","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","article-title":"MolProbity: all-atom structure validation for macromolecular crystallography","volume":"66","author":"Chen VB","year":"2010","unstructured":"Chen VB et al (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66:12\u201321","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nsmb.3115","article-title":"Privateer: software for the conformational validation of carbohydrate structures","volume":"22","author":"Agirre J","year":"2015","unstructured":"Agirre J et al (2015) Privateer: software for the conformational validation of carbohydrate structures. Nat Struct Mol Biol 22:833\u2013834","journal-title":"Nat Struct Mol Biol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/nmeth.3541","article-title":"EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy","volume":"12","author":"Barad BA","year":"2015","unstructured":"Barad BA et al (2015) EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy. Nat Methods 12:943\u2013946","journal-title":"Nat Methods"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9917568\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9917568\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:48:19Z","timestamp":1782287299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9917568\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":33,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9917568\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,6,24]]},"subtype":"preprint"}}